Category - Developments

Developments

Silo partners with global CRO for preclinical study to advance homing peptide in MS

Silo Pharma (NASDAQ:SILO) has entered into an agreement with WuXi AppTec for a preclinical small animal study of SPU-16, a central nervous system (CNS) homing peptide targeting multiple sclerosis (MS). Silo Pharma is...

August 7, 2024

Developments

Quoin Pharma plans clinical study of peeling skin syndrome in children

Quoin Pharmaceuticals (NASDAQ:QNRX) announced plans to initiate an investigator-led clinical study to evaluate the safety and efficacy of QRX003 in pediatric patients with peeling skin syndrome (PSS). The study will be...

August 6, 2024

Developments

Abivax achieves key enrollment milestone in Phase 3 trial of Obefazimod in UC

Abivax SA (Euronext Paris, NASDAQ:ABVX) reports reaching the 600-patient enrollment milestone for its Phase 3 ABTECT trial to evaluate its lead investigational drug candidate, Obefazimod, in patients with moderate-to...

August 6, 2024

Developments

Anebulo announces NIDA grant for investigational treatment of acute cannabis-induced toxicities in children

Anebulo Pharmaceuticals (NASDAQ:ANEB) has been awarded the first tranche of a two-year, $1.9 million NIDA grant to develop intravenous selonabant for treating acute cannabis-induced toxicity, including CNS depression in...

July 22, 2024

Developments

Clearmind files additional U.S. patent application for MEAI to treat obesity

Clearmind Medicine (NASDAQ:CMND; FSE:CWYO) announced it has filed an additional patent application with the USPTO for the novel proprietary composition of its MEAI compound for treating metabolic syndrome and obesity...

July 16, 2024

Developments

Alto Neuroscience announces Phase 2b enrollment completion in MDD study

Alto Neuroscience (NYSE:ANRO) announced the completion of enrollment in its Phase 2b study evaluating ALTO-100 in 300 adults with major depressive disorder (MDD) across 34 U.S. sites. The randomized, double-blind...

July 16, 2024

Developments

CMS unveils proposed reimbursement for TULSA to treat prostate disease

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that the U.S. Centers for Medicare and Medicaid Services has issued proposed rules establishing, for the first time, a Category 1 CPT code for the Transurethral...

July 12, 2024

Developments

Rainhouse spotlights CNN reveal on injection cartridge supply issues impacting weight-loss drug shortages

Rainhouse Manufacturing Canada, a well-established North American CNC machining and manufacturing company, emphasized a recent CNN interview with Dr. Sanjay Gupta, which uncovered the real cause of weight-loss drug...

July 12, 2024

Developments

Remembering Elias Vamvakas, a friend and mentor

For the first time since we began publishing in 2009, the BioTuesdays family is lost for words, almost. With devastating sadness, we learned today of Elias Vamvakas’ passing. A pioneering entrepreneur in the Canadian...

July 11, 2024

Developments

Exscientia launches AWS AI-powered platform to advance drug discovery

Exscientia plc (NASDAQ:EXAI) announced its use of Amazon Web Services (AWS) artificial intelligence and machine learning services to power its platform for end-to-end drug discovery and automation. Exscientia’s...

July 10, 2024

Category - Developments

Subscribe